protection malaria intravenous immunization nonreplicating sporozoite vaccine
consistent high-level vaccine-induced protection human malaria achieved inoculation plasmodium falciparum pf sporozoites spz mosquito bites report pfspz vaccine-composed attenuated aseptic purified cryopreserved pfspz-was safe well tolerated administered four six times intravenously iv adults zero six subjects receiving five doses three nine subjects receiving four doses x pfspz vaccine five six nonvaccinated controls developed malaria controlled human malaria infection p five-dose group p overall versus controls pfspz-specific antibody t cell responses dose-dependent data indicate dose-dependent immunological threshold establishing high-level protection malaria can achieved iv administration vaccine safe meets regulatory standards
